TD Cowen Names Enliven Therapeutics (ELVN) Best Smidcap Idea

TD Cowen analyst Phil Nadaeu reiterated a Buy rating and {REMOVEPT} price target on Enliven Therapeutics (NASDAQ: ELVN).

The analyst commented: "Best Smidcap Ideas: Strong Data Position '001 To Advance Care In $B+ CML Market; ELVN-001 is designed to improve upon prior TKIs for CML. At EHA ELVN-001 produced strong proof-of-concept data with a high MMR rate and benign safety profile, positioning it to become a standard therapy in this multi-$B market. ELVN-001 will enter pivotal development in 2026 and we project peak sales of $3B. We think ELVN is undervalued for '001's potential. It is a top smidcap biotech pick."

For an analyst ratings summary and ratings history on Enliven Therapeutics click here. For more ratings news on Enliven Therapeutics click here.

Shares of Enliven Therapeutics closed at $21.57 yesterday.

You May Also Be Interested In

• BofA maintains underperform ratings on six BDC stocks
• Myriad Uranium completes acquisition of Rush Rare Metals
• Boeing names Ryan Shedd as new SVP and controller